Fig. 2: HFF, hepatic fatty acid composition and body weight, and fasting and postprandial blood glucose (part B).
a, Mean change from baseline to day 35 of treatment in fasting HFF, measured using MRI–PDFF. b–d, Proportional composition of fatty acids in the liver at day 35 of treatment. e, Mean change from baseline to day 35 of treatment in body weight. f, Mean change from baseline to day 35 of treatment in fasting plasma glucose. g, Mean relative change from baseline to day 35 of treatment in postprandial plasma glucose (AUC0–220 min) after the MMTT. Patients who were evaluated in a: placebo, n = 10; liraglutide, n = 7; cotadutide, n = 6. Patients who were evaluated in b–d: placebo, n = 7; liraglutide, n = 6; cotadutide, n = 5. Patients who were evaluated in e: placebo, n = 11; liraglutide, n = 10; cotadutide, n = 9. Patients who were evaluated in f and g: placebo, n = 11; liraglutide, n = 9; cotadutide, n = 9. Data in a and e are the mean ± s.d., with overlayed individual data points. Data in b–d are the mean ± s.e.m. Data in f and g are the mean and overlayed individual data points. Two-sided P values from the ANCOVA model adjusting for baseline value and treatment group are shown, with no corrections for multiple comparisons.
